Insulin in the nervous system and the mind: Functions in metabolism, memory, and mood

Molecular Metabolism

Volumn 5, Issue 8, 2016, Pages 589-601

  Lee, Seung Hwan ^a,b   Zabolotny, Janice M ^a   Huang, Hu ^a,c   Lee, Hyon ^d   Kim, Young Bum ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b The Catholic University of Korea   (South Korea)

^c EAST CAROLINA UNIVERSITY   (United States)

^d Gachon University College of Medicine   (South Korea)

Author keywords

Insulin; Intranasal insulin; Memory; Metabolism; Mood

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; C PEPTIDE; CORTICOTROPIN; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE ACETYLTRANSFERASE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 2; MELANOCORTIN 4 RECEPTOR; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; N ACETYLGLUCOSAMINE; N METHYL DEXTRO ASPARTIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE 1B; STEROIDOGENIC FACTOR 1; STRESS ACTIVATED PROTEIN KINASE; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR FKHR; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; BIPOLAR DISORDER; BLOOD BRAIN BARRIER; BODY WEIGHT; BRAIN FUNCTION; BRAIN LEVEL; CENTRAL NERVOUS SYSTEM; COGNITION; CONNECTOME; DEMENTIA; DEPRESSION; ENERGY METABOLISM; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HORMONE ACTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MEMORY; MEMORY DISORDER; METABOLIC DISORDER; MILD COGNITIVE IMPAIRMENT; MOOD; MOOD DISORDER; NERVE CELL PLASTICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84977083882     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2016.06.011     Document Type: Review

References (148)

1. [1] Samuel, V.T., Shulman, G.I., Mechanisms for insulin resistance: common threads and missing links. Cell 148 (2012), 852–871.
2. [2] Schwartz, M.W., Porte, D. Jr., Diabetes, obesity, and the brain. Science 307 (2005), 375–379.
3. [3] Plum, L., Schubert, M., Bruning, J.C., The role of insulin receptor signaling in the brain. Trends in Endocrinology and Metabolism 16 (2005), 59–65.
4. [4] Choi, K., Kim, Y.B., Molecular mechanism of insulin resistance in obesity and type 2 diabetes. Korean Journal of Internal Medicine 25 (2010), 119–129.
5. [5] Havrankova, J., Roth, J., Brownstein, M., Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272 (1978), 827–829.
6. [6] Banks, W.A., Owen, J.B., Erickson, M.A., Insulin in the brain: there and back again. Pharmacology & Therapeutics 136 (2012), 82–93.
7. [7] Bruning, J.C., Gautam, D., Burks, D.J., Gillette, J., Schubert, M., Orban, P.C., et al. Role of brain insulin receptor in control of body weight and reproduction. Science 289 (2000), 2122–2125.
8. [8] Obici, S., Zhang, B.B., Karkanias, G., Rossetti, L., Hypothalamic insulin signaling is required for inhibition of glucose production. Nature Medicine 8 (2002), 1376–1382.
9. [9] Scherer, T., O'Hare, J., Diggs-Andrews, K., Schweiger, M., Cheng, B., Lindtner, C., et al. Brain insulin controls adipose tissue lipolysis and lipogenesis. Cell Metabolism 13 (2011), 183–194.
10. [10] Kleinridders, A., Cai, W., Cappellucci, L., Ghazarian, A., Collins, W.R., Vienberg, S.G., et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proceedings of the National Academy of Sciences of the United States of America 112 (2015), 3463–3468.
11. [11] Costello, D.A., Claret, M., Al-Qassab, H., Plattner, F., Irvine, E.E., Choudhury, A.I., et al. Brain deletion of insulin receptor substrate 2 disrupts hippocampal synaptic plasticity and metaplasticity. PLoS One, 7, 2012, e31124.
12. [12] Defronzo, R.A., Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58 (2009), 773–795.
13. [13] Banks, W.A., Jaspan, J.B., Kastin, A.J., Selective, physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides 18 (1997), 1257–1262.
14. [14] Banks, W.A., Kastin, A.J., Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides 19 (1998), 883–889.
15. [15] Reger, M.A., Watson, G.S., Frey, W.H. 2nd, Baker, L.D., Cholerton, B., Keeling, M.L., et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiology of Aging 27 (2006), 451–458.
16. [16] Heni, M., Schopfer, P., Peter, A., Sartorius, T., Fritsche, A., Synofzik, M., et al. Evidence for altered transport of insulin across the blood-brain barrier in insulin-resistant humans. Acta Diabetologica 51 (2014), 679–681.
17. [17] Tschritter, O., Preissl, H., Hennige, A.M., Stumvoll, M., Porubska, K., Frost, R., et al. The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proceedings of the National Academy of Sciences of the United States of America 103 (2006), 12103–12108.
18. [18] Dorn, A., Bernstein, H.G., Rinne, A., Ziegler, M., Hahn, H.J., Ansorge, S., Insulin- and glucagonlike peptides in the brain. Anatomical Record 207 (1983), 69–77.
19. [19] Dorn, A., Bernstein, H.G., Rinne, A., Hahn, H.J., Ziegler, M., Insulin-like immunoreactivity in the human brain- a preliminary report. Histochemistry 74 (1982), 293–300.
20. [20] Ghasemi, R., Haeri, A., Dargahi, L., Mohamed, Z., Ahmadiani, A., Insulin in the brain: sources, localization and functions. Molecular Neurobiology 47 (2013), 145–171.
21. [21] Birch, N.P., Christie, D.L., Renwick, A.G., Proinsulin-like material in mouse foetal brain cell cultures. FEBS Letters 168 (1984), 299–302.
22. [22] Born, J., Lange, T., Kern, W., McGregor, G.P., Bickel, U., Fehm, H.L., Sniffing neuropeptides: a transnasal approach to the human brain. Nature Neuroscience 5 (2002), 514–516.
23. [23] Thorne, R.G., Emory, C.R., Ala, T.A., Frey, W.H. 2nd, Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Research 692 (1995), 278–282.
24. [24] Illum, L., Transport of drugs from the nasal cavity to the central nervous system. European Journal of Pharmaceutical Sciences 11 (2000), 1–18.
25. [25] Renner, D.B., Svitak, A.L., Gallus, N.J., Ericson, M.E., Frey, W.H. 2nd, Hanson, L.R., Intranasal delivery of insulin via the olfactory nerve pathway. Journal of Pharmacy and Pharmacology 64 (2012), 1709–1714.
26. [26] Chapman, C.D., Frey, W.H. 2nd, Craft, S., Danielyan, L., Hallschmid, M., Schioth, H.B., et al. Intranasal treatment of central nervous system dysfunction in humans. Pharmaceutical Research 30 (2013), 2475–2484.
27. [27] Major, R.H., The intranasal application of insulin, experimental and clinical experiences. Transactions of the American Clinical and Climatological Association 51 (1935), 21–27.
28. [28] Kaiyala, K.J., Prigeon, R.L., Kahn, S.E., Woods, S.C., Schwartz, M.W., Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 49 (2000), 1525–1533.
29. [29] Stein, L.J., Dorsa, D.M., Baskin, D.G., Figlewicz, D.P., Porte, D. Jr., Woods, S.C., Reduced effect of experimental peripheral hyperinsulinemia to elevate cerebrospinal fluid insulin concentrations of obese Zucker rats. Endocrinology 121 (1987), 1611–1615.
30. [30] Schwartz, M.W., Figlewicz, D.P., Baskin, D.G., Woods, S.C., Porte, D. Jr., Insulin in the brain: a hormonal regulator of energy balance. Endocrine Reviews 13 (1992), 387–414.
31. [31] Kim, Y.B., Nikoulina, S.E., Ciaraldi, T.P., Henry, R.R., Kahn, B.B., Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. The Journal of Clinical Investigation 104 (1999), 733–741.
32. [32] Clegg, D.J., Gotoh, K., Kemp, C., Wortman, M.D., Benoit, S.C., Brown, L.M., et al. Consumption of a high-fat diet induces central insulin resistance independent of adiposity. Physiology & Behavior 103 (2011), 10–16.
33. [33] Niswender, K.D., Morrison, C.D., Clegg, D.J., Olson, R., Baskin, D.G., Myers, M.G. Jr., et al. Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus: a key mediator of insulin-induced anorexia. Diabetes 52 (2003), 227–231.
34. [34] Chen, M., Woods, S.C., Porte, D. Jr., Effect of cerebral intraventricular insulin on pancreatic insulin secretion in the dog. Diabetes 24 (1975), 910–914.
35. [35] Woods, S.C., Lotter, E.C., McKay, L.D., Porte, D. Jr., Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature 282 (1979), 503–505.
36. [36] Harai, S., Ikenaga, T., Matsuzawa, T., Nasal absorption of insulin in dogs. Diabetes 27 (1978), 296–299.
37. [37] Anand Kumar, T.C., Sehgal, A., Bajaj, J.S., Intranasal administration of insulin reduces circulating levels of glucose in the Rhesus monkey. Current Science 49 (1980), 548–550.
38. [38] Obici, S., Feng, Z., Karkanias, G., Baskin, D.G., Rossetti, L., Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nature Neuroscience 5 (2002), 566–572.
39. [39] Grillo, C.A., Tamashiro, K.L., Piroli, G.G., Melhorn, S., Gass, J.T., Newsom, R.J., et al. Lentivirus-mediated downregulation of hypothalamic insulin receptor expression. Physiology & Behavior 92 (2007), 691–701.
40. [40] Paranjape, S.A., Chan, O., Zhu, W., Horblitt, A.M., Grillo, C.A., Wilson, S., et al. Chronic reduction of insulin receptors in the ventromedial hypothalamus produces glucose intolerance and islet dysfunction in the absence of weight gain. American Journal of Physiology. Endocrinology and Metabolism 301 (2011), E978–E983.
41. [41] Konner, A.C., Janoschek, R., Plum, L., Jordan, S.D., Rother, E., Ma, X., et al. Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. Cell Metabolism 5 (2007), 438–449.
42. [42] Varela, L., Horvath, T.L., Leptin and insulin pathways in POMC and AgRP neurons that modulate energy balance and glucose homeostasis. EMBO Reports 13 (2012), 1079–1086.
43. [43] Hill, J.W., Elias, C.F., Fukuda, M., Williams, K.W., Berglund, E.D., Holland, W.L., et al. Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility. Cell Metabolism 11 (2010), 286–297.
44. [44] Sipols, A.J., Baskin, D.G., Schwartz, M.W., Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes 44 (1995), 147–151.
45. [45] Benoit, S.C., Air, E.L., Coolen, L.M., Strauss, R., Jackman, A., Clegg, D.J., et al. The catabolic action of insulin in the brain is mediated by melanocortins. The Journal of Neuroscience 22 (2002), 9048–9052.
46. [46] Balthasar, N., Dalgaard, L.T., Lee, C.E., Yu, J., Funahashi, H., Williams, T., et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123 (2005), 493–505.
47. [47] Kim, M.S., Pak, Y.K., Jang, P.G., Namkoong, C., Choi, Y.S., Won, J.C., et al. Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nature Neuroscience 9 (2006), 901–906.
48. [48] Kitamura, T., Feng, Y., Kitamura, Y.I., Chua, S.C. Jr., Xu, A.W., Barsh, G.S., et al. Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake. Nature Medicine 12 (2006), 534–540.
49. [49] Belgardt, B.F., Okamura, T., Bruning, J.C., Hormone and glucose signalling in POMC and AgRP neurons. The Journal of Physiology 587 (2009), 5305–5314.
50. [50] Lin, H.V., Plum, L., Ono, H., Gutierrez-Juarez, R., Shanabrough, M., Borok, E., et al. Divergent regulation of energy expenditure and hepatic glucose production by insulin receptor in agouti-related protein and POMC neurons. Diabetes 59 (2010), 337–346.
51. [51] Yaswen, L., Diehl, N., Brennan, M.B., Hochgeschwender, U., Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nature Medicine 5 (1999), 1066–1070.
52. [52] Gropp, E., Shanabrough, M., Borok, E., Xu, A.W., Janoschek, R., Buch, T., et al. Agouti-related peptide-expressing neurons are mandatory for feeding. Nature Neuroscience 8 (2005), 1289–1291.
53. [53] Dhillon, H., Zigman, J.M., Ye, C., Lee, C.E., McGovern, R.A., Tang, V., et al. Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis. Neuron 49 (2006), 191–203.
54. [54] Kim, K.W., Sohn, J.W., Kohno, D., Xu, Y., Williams, K., Elmquist, J.K., SF-1 in the ventral medial hypothalamic nucleus: a key regulator of homeostasis. Molecular and Cellular Endocrinology 336 (2011), 219–223.
55. [55] Klockener, T., Hess, S., Belgardt, B.F., Paeger, L., Verhagen, L.A., Husch, A., et al. High-fat feeding promotes obesity via insulin receptor/PI3K-dependent inhibition of SF-1 VMH neurons. Nature Neuroscience 14 (2011), 911–918.
56. [56] Williams, K.W., Margatho, L.O., Lee, C.E., Choi, M., Lee, S., Scott, M.M., et al. Segregation of acute leptin and insulin effects in distinct populations of arcuate proopiomelanocortin neurons. The Journal of Neuroscience 30 (2010), 2472–2479.
57. [57] Heni, M., Kullmann, S., Ketterer, C., Guthoff, M., Linder, K., Wagner, R., et al. Nasal insulin changes peripheral insulin sensitivity simultaneously with altered activity in homeostatic and reward-related human brain regions. Diabetologia 55 (2012), 1773–1782.
58. [58] Stockhorst, U., de Fries, D., Steingrueber, H.J., Scherbaum, W.A., Unconditioned and conditioned effects of intranasally administered insulin vs placebo in healthy men: a randomised controlled trial. Diabetologia 54 (2011), 1502–1506.
59. [59] Pontiroli, A.E., Alberetto, M., Secchi, A., Dossi, G., Bosi, I., Pozza, G., Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects. British Medical Journal (Clinical Research Ed.) 284 (1982), 303–306.
60. [60] Moses, A.C., Gordon, G.S., Carey, M.C., Flier, J.S., Insulin administered intranasally as an insulin-bile salt aerosol. Effectiveness and reproducibility in normal and diabetic subjects. Diabetes 32 (1983), 1040–1047.
61. [61] Salzman, R., Manson, J.E., Griffing, G.T., Kimmerle, R., Ruderman, N., McCall, A., et al. Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes. The New England Journal of Medicine 312 (1985), 1078–1084.
62. [62] Frauman, A.G., Cooper, M.E., Parsons, B.J., Jerums, G., Louis, W.J., Long-term use of intranasal insulin in insulin-dependent diabetic patients. Diabetes Care 10 (1987), 573–578.
63. [63] Frauman, A.G., Jerums, G., Louis, W.J., Effects of intranasal insulin in non-obese type II diabetics. Diabetes Research and Clinical Practice 3 (1987), 197–202.
64. [64] Paquot, N., Scheen, A.J., Franchimont, P., Lefebvre, P.J., The intra-nasal administration of insulin induces significant hypoglycaemia and classical counterregulatory hormonal responses in normal man. Diabetes & Metabolism 14 (1988), 31–36.
65. [65] Coates, P.A., Ismail, I.S., Luzio, S.D., Griffiths, I., Ollerton, R.L., Volund, A., et al. Intranasal insulin: the effects of three dose regimens on postprandial glycaemic profiles in type II diabetic subjects. Diabetes Medicine 12 (1995), 235–239.
66. [66] Lalej-Bennis, D., Boillot, J., Bardin, C., Zirinis, P., Coste, A., Escudier, E., et al. Efficacy and tolerance of intranasal insulin administered during 4 months in severely hyperglycaemic Type 2 diabetic patients with oral drug failure: a cross-over study. Diabetes Medicine 18 (2001), 614–618.
67. [67] Bruce, D.G., Chisholm, D.J., Storlien, L.H., Borkman, M., Kraegen, E.W., Meal-time intranasal insulin delivery in type 2 diabetes. Diabetes Medicine 8 (1991), 366–370.
68. [68] Hilsted, J., Madsbad, S., Hvidberg, A., Rasmussen, M.H., Krarup, T., Ipsen, H., et al. Intranasal insulin therapy: the clinical realities. Diabetologia 38 (1995), 680–684.
69. [69] Kern, W., Born, J., Schreiber, H., Fehm, H.L., Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes 48 (1999), 557–563.
70. [70] Benedict, C., Brede, S., Schioth, H.B., Lehnert, H., Schultes, B., Born, J., et al. Intranasal insulin enhances postprandial thermogenesis and lowers postprandial serum insulin levels in healthy men. Diabetes 60 (2011), 114–118.
71. [71] Heni, M., Wagner, R., Kullmann, S., Veit, R., Mat Husin, H., Linder, K., et al. Central insulin administration improves whole-body insulin sensitivity via hypothalamus and parasympathetic outputs in men. Diabetes 63 (2014), 4083–4088.
72. [72] Benedict, C., Kern, W., Schultes, B., Born, J., Hallschmid, M., Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. The Journal of Clinical Endocrinology & Metabolism 93 (2008), 1339–1344.
73. [73] Krug, R., Benedict, C., Born, J., Hallschmid, M., Comparable sensitivity of postmenopausal and young women to the effects of intranasal insulin on food intake and working memory. The Journal of Clinical Endocrinology & Metabolism 95 (2010), E468–E472.
74. [74] Hallschmid, M., Benedict, C., Schultes, B., Fehm, H.L., Born, J., Kern, W., Intranasal insulin reduces body fat in men but not in women. Diabetes 53 (2004), 3024–3029.
75. [75] Hallschmid, M., Higgs, S., Thienel, M., Ott, V., Lehnert, H., Postprandial administration of intranasal insulin intensifies satiety and reduces intake of palatable snacks in women. Diabetes 61 (2012), 782–789.
76. [76] Jauch-Chara, K., Friedrich, A., Rezmer, M., Melchert, U.H., G.S.-E., H., Hallschmid, M., et al. Intranasal insulin suppresses food intake via enhancement of brain energy levels in humans. Diabetes 61 (2012), 2261–2268.
77. [77] Guthoff, M., Grichisch, Y., Canova, C., Tschritter, O., Veit, R., Hallschmid, M., et al. Insulin modulates food-related activity in the central nervous system. The Journal of Clinical Endocrinology & Metabolism 95 (2010), 748–755.
78. [78] Kullmann, S., Frank, S., Heni, M., Ketterer, C., Veit, R., Haring, H.U., et al. Intranasal insulin modulates intrinsic reward and prefrontal circuitry of the human brain in lean women. Neuroendocrinology 97 (2013), 176–182.
79. [79] Kullmann, S., Heni, M., Veit, R., Scheffler, K., Machann, J., Haring, H.U., et al. Selective insulin resistance in homeostatic and cognitive control brain areas in overweight and obese adults. Diabetes Care 38 (2015), 1044–1050.
80. [80] Hallschmid, M., Benedict, C., Schultes, B., Born, J., Kern, W., Obese men respond to cognitive but not to catabolic brain insulin signaling. International Journal of Obesity (London) 32 (2008), 275–282.
81. [81] James, F.E., Insulin treatment in psychiatry. History of Psychiatry 3 (1992), 221–235.
82. [82] Sakel, M., The origin and nature of the hypoglycemic therapy of the psychoses. Bulletin of the New York Academy of Medicine 13 (1937), 97–109.
83. [83] Mack, C.W., Burch, B.O., Insulin shock therapy in dementia praecox: a report of a series of cases. California and Western Medicine 50 (1939), 339–344.
84. [84] Crammer, J.L., Insulin coma therapy for schizophrenia. Journal of the Royal Society of Medicine 93 (2000), 332–333.
85. [85] Berman, L., Riess, B., The effect of insulin shock on learning in the white rat. Science 95 (1942), 511–512.
86. [86] Stranahan, A.M., Norman, E.D., Lee, K., Cutler, R.G., Telljohann, R.S., Egan, J.M., et al. Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 18 (2008), 1085–1088.
87. [87] Biessels, G.J., Reagan, L.P., Hippocampal insulin resistance and cognitive dysfunction. Nature Reviews Neuroscience 16 (2015), 660–671.
88. [88] Zhao, W.Q., De Felice, F.G., Fernandez, S., Chen, H., Lambert, M.P., Quon, M.J., et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB Journal 22 (2008), 246–260.
89. [89] de la Monte, S.M., Wands, J.R., Alzheimer's disease is type 3 diabetes-evidence reviewed. The Journal of Diabetes Science and Technology 2 (2008), 1101–1113.
90. [90] Querfurth, H.W., LaFerla, F.M., Alzheimer's disease. The New England Journal of Medicine 362 (2010), 329–344.
91. [91] Arvanitakis, Z., Wilson, R.S., Bienias, J.L., Evans, D.A., Bennett, D.A., Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Archives of Neurology 61 (2004), 661–666.
92. [92] Whitmer, R.A., Gustafson, D.R., Barrett-Connor, E., Haan, M.N., Gunderson, E.P., Yaffe, K., Central obesity and increased risk of dementia more than three decades later. Neurology 71 (2008), 1057–1064.
93. [93] Biessels, G.J., Staekenborg, S., Brunner, E., Brayne, C., Scheltens, P., Risk of dementia in diabetes mellitus: a systematic review. The Lancet Neurology 5 (2006), 64–74.
94. [94] Lee, J.H., Choi, Y., Jun, C., Hong, Y.S., Cho, H.B., Kim, J.E., et al. Neurocognitive changes and their neural correlates in patients with type 2 diabetes mellitus. Endocrinology & Metabolism (Seoul) 29 (2014), 112–121.
95. [95] Chatterjee, S., Peters, S.A., Woodward, M., Arango, S.M., Batty, G.D., Beckett, N., et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care 39 (2016), 300–307.
96. [96] Gudala, K., Bansal, D., Schifano, F., Bhansali, A., Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. Journal of Diabetes Investigation 4 (2013), 640–650.
97. [97] Blazquez, E., Velazquez, E., Hurtado-Carneiro, V., Ruiz-Albusac, J.M., Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease. Frontiers in Endocrinology (Lausanne), 5, 2014, 161.
98. [98] de la Monte, S.M., Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Current Alzheimer Research 9 (2012), 35–66.
99. [99] Willette, A.A., Xu, G., Johnson, S.C., Birdsill, A.C., Jonaitis, E.M., Sager, M.A., et al. Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults. Diabetes Care 36 (2013), 443–449.
100. [100] Talbot, K., Wang, H.Y., Kazi, H., Han, L.Y., Bakshi, K.P., Stucky, A., et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. The Journal of Clinical Investigation 122 (2012), 1316–1338.
101. [101] Liu, Y., Liu, F., Grundke-Iqbal, I., Iqbal, K., Gong, C.X., Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. The Journal of Pathology 225 (2011), 54–62.
102. [102] Deng, Y., Li, B., Liu, Y., Iqbal, K., Grundke-Iqbal, I., Gong, C.X., Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer's disease. American Journal of Pathology 175 (2009), 2089–2098.
103. [103] Takashima, A., GSK-3 is essential in the pathogenesis of Alzheimer's disease. Journal of Alzheimer's Disease 9 (2006), 309–317.
104. [104] Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G.W., Gong, C.X., O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 101 (2004), 10804–10809.
105. [105] Yuzwa, S.A., Shan, X., Macauley, M.S., Clark, T., Skorobogatko, Y., Vosseller, K., et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nature Chemical Biology 8 (2012), 393–399.
106. [106] Bomfim, T.R., Forny-Germano, L., Sathler, L.B., Brito-Moreira, J., Houzel, J.C., Decker, H., et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers. The Journal of Clinical Investigation 122 (2012), 1339–1353.
107. [107] Mielke, J.G., Taghibiglou, C., Liu, L., Zhang, Y., Jia, Z., Adeli, K., et al. A biochemical and functional characterization of diet-induced brain insulin resistance. Journal of Neurochemistry 93 (2005), 1568–1578.
108. [108] Pratchayasakul, W., Kerdphoo, S., Petsophonsakul, P., Pongchaidecha, A., Chattipakorn, N., Chattipakorn, S.C., Effects of high-fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticosterone. Life Sciences 88 (2011), 619–627.
109. [109] Pipatpiboon, N., Pratchayasakul, W., Chattipakorn, N., Chattipakorn, S.C., PPARgamma agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology 153 (2012), 329–338.
110. [110] Pipatpiboon, N., Pintana, H., Pratchayasakul, W., Chattipakorn, N., Chattipakorn, S.C., DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. European Journal of Neuroscience 37 (2013), 839–849.
111. [111] Ho, N., Balu, D.T., Hilario, M.R., Blendy, J.A., Lucki, I., Depressive phenotypes evoked by experimental diabetes are reversed by insulin. Physiology & Behavior 105 (2012), 702–708.
112. [112] Ho, L., Qin, W., Pompl, P.N., Xiang, Z., Wang, J., Zhao, Z., et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB Journal 18 (2004), 902–904.
113. [113] Townsend, M., Mehta, T., Selkoe, D.J., Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. The Journal of Biological Chemistry 282 (2007), 33305–33312.
114. [114] Schubert, M., Gautam, D., Surjo, D., Ueki, K., Baudler, S., Schubert, D., et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proceedings of the National Academy of Sciences of the United States of America 101 (2004), 3100–3105.
115. [115] Freude, S., Hettich, M.M., Schumann, C., Stohr, O., Koch, L., Kohler, C., et al. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB Journal 23 (2009), 3315–3324.
116. [116] Marks, D.R., Tucker, K., Cavallin, M.A., Mast, T.G., Fadool, D.A., Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. The Journal of Neuroscience 29 (2009), 6734–6751.
117. [117] Das, P., Parsons, A.D., Scarborough, J., Hoffman, J., Wilson, J., Thompson, R.N., et al. Electrophysiological and behavioral phenotype of insulin receptor defective mice. Physiology & Behavior 86 (2005), 287–296.
118. [118] Yang, Y., Ma, D., Wang, Y., Jiang, T., Hu, S., Zhang, M., et al. Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes. Journal of Alzheimer's Disease 33 (2013), 329–338.
119. [119] Benedict, C., Hallschmid, M., Hatke, A., Schultes, B., Fehm, H.L., Born, J., et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29 (2004), 1326–1334.
120. [120] Novak, V., Milberg, W., Hao, Y., Munshi, M., Novak, P., Galica, A., et al. Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes. Diabetes Care 37 (2014), 751–759.
121. [121] Reger, M.A., Watson, G.S., Green, P.S., Baker, L.D., Cholerton, B., Fishel, M.A., et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. Journal of Alzheimer's Disease 13 (2008), 323–331.
122. [122] Benedict, C., Hallschmid, M., Schmitz, K., Schultes, B., Ratter, F., Fehm, H.L., et al. Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 32 (2007), 239–243.
123. [123] Reger, M.A., Watson, G.S., Green, P.S., Wilkinson, C.W., Baker, L.D., Cholerton, B., et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70 (2008), 440–448.
124. [124] Craft, S., Baker, L.D., Montine, T.J., Minoshima, S., Watson, G.S., Claxton, A., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Archives of Neurology 69 (2012), 29–38.
125. [125] Cowie, D.M., Parsons, J.P., Raphael, T., Insulin and mental depression. Archives of Neurology and Psychiatry 12 (1924), 522–533.
126. [126] Rubin, R.R., Peyrot, M., Was Willis right? Thoughts on the interaction of depression and diabetes. Diabetes/Metabolism Research and Reviews 18 (2002), 173–175.
127. [127] Musselman, D.L., Betan, E., Larsen, H., Phillips, L.S., Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biological Psychiatry 54 (2003), 317–329.
128. [128] Silva, N., Atlantis, E., Ismail, K., A review of the association between depression and insulin resistance: pitfalls of secondary analyses or a promising new approach to prevention of type 2 diabetes?. Current Psychiatry Reports 14 (2012), 8–14.
129. [129] Baker, L.D., Cross, D.J., Minoshima, S., Belongia, D., Watson, G.S., Craft, S., Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Archives of Neurology 68 (2011), 51–57.
130. [130] Chen, Z., Zhong, C., Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Progress in Neurobiology 108 (2013), 21–43.
131. [131] Su, L., Cai, Y., Xu, Y., Dutt, A., Shi, S., Bramon, E., Cerebral metabolism in major depressive disorder: a voxel-based meta-analysis of positron emission tomography studies. BMC Psychiatry, 14, 2014, 321.
132. [132] Domenici, E., Wille, D.R., Tozzi, F., Prokopenko, I., Miller, S., McKeown, A., et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One, 5, 2010, e9166.
133. [133] Pan, Y., Hong, Y., Zhang, Q.Y., Kong, L.D., Impaired hypothalamic insulin signaling in CUMS rats: restored by icariin and fluoxetine through inhibiting CRF system. Psychoneuroendocrinology 38 (2013), 122–134.
134. [134] Grillo, C.A., Piroli, G.G., Kaigler, K.F., Wilson, S.P., Wilson, M.A., Reagan, L.P., Downregulation of hypothalamic insulin receptor expression elicits depressive-like behaviors in rats. Behavioural Brain Research 222 (2011), 230–235.
135. [135] Cline, B.H., Steinbusch, H.W., Malin, D., Revishchin, A.V., Pavlova, G.V., Cespuglio, R., et al. The neuronal insulin sensitizer dicholine succinate reduces stress-induced depressive traits and memory deficit: possible role of insulin-like growth factor 2. BMC Neuroscience, 13, 2012, 110.
136. [136] Bohringer, A., Schwabe, L., Richter, S., Schachinger, H., Intranasal insulin attenuates the hypothalamic-pituitary-adrenal axis response to psychosocial stress. Psychoneuroendocrinology 33 (2008), 1394–1400.
137. [137] McIntyre, R.S., Soczynska, J.K., Woldeyohannes, H.O., Miranda, A., Vaccarino, A., Macqueen, G., et al. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disorder 14 (2012), 697–706.
138. [138] Konner, A.C., Hess, S., Tovar, S., Mesaros, A., Sanchez-Lasheras, C., Evers, N., et al. Role for insulin signaling in catecholaminergic neurons in control of energy homeostasis. Cell Metabolism 13 (2011), 720–728.
139. [139] Fisher, S.J., Bruning, J.C., Lannon, S., Kahn, C.R., Insulin signaling in the central nervous system is critical for the normal sympathoadrenal response to hypoglycemia. Diabetes 54 (2005), 1447–1451.
140. [140] Diggs-Andrews, K.A., Zhang, X., Song, Z., Daphna-Iken, D., Routh, V.H., Fisher, S.J., Brain insulin action regulates hypothalamic glucose sensing and the counterregulatory response to hypoglycemia. Diabetes 59 (2010), 2271–2280.
141. [141] Sanchez-Alavez, M., Osborn, O., Tabarean, I.V., Holmberg, K.H., Eberwine, J., Kahn, C.R., et al. Insulin-like growth factor 1-mediated hyperthermia involves anterior hypothalamic insulin receptors. The Journal of Biological Chemistry 286 (2011), 14983–14990.
142. [142] Stohr, O., Schilbach, K., Moll, L., Hettich, M.M., Freude, S., Wunderlich, F.T., et al. Insulin receptor signaling mediates APP processing and beta-amyloid accumulation without altering survival in a transgenic mouse model of Alzheimer's disease. Age (Dordrecht) 35 (2013), 83–101.
143. [143] Iwen, K.A., Scherer, T., Heni, M., Sayk, F., Wellnitz, T., Machleidt, F., et al. Intranasal insulin suppresses systemic but not subcutaneous lipolysis in healthy humans. The Journal of Clinical Endocrinology & Metabolism 99 (2014), E246–E251.
144. [144] Gancheva, S., Koliaki, C., Bierwagen, A., Nowotny, P., Heni, M., Fritsche, A., et al. Effects of intranasal insulin on hepatic fat accumulation and energy metabolism in humans. Diabetes 64 (2015), 1966–1975.
145. [145] Rosenbloom, M.H., Barclay, T.R., Pyle, M., Owens, B.L., Cagan, A.B., Anderson, C.P., et al. A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease. CNS Drugs 28 (2014), 1185–1189.
146. [146] Brunner, Y.F., Kofoet, A., Benedict, C., Freiherr, J., Central insulin administration improves odor-cued reactivation of spatial memory in young men. The Journal of Clinical Endocrinology & Metabolism 100 (2015), 212–219.
147. [147] Claxton, A., Baker, L.D., Hanson, A., Trittschuh, E.H., Cholerton, B., Morgan, A., et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. Journal of Alzheimer's Disease 44 (2015), 897–906.
148. [148] Zhang, H., Hao, Y., Manor, B., Novak, P., Milberg, W., Zhang, J., et al. Intranasal insulin enhanced resting-state functional connectivity of hippocampal regions in type 2 diabetes. Diabetes 64 (2015), 1025–1034.